JP2013503621A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503621A5
JP2013503621A5 JP2012527383A JP2012527383A JP2013503621A5 JP 2013503621 A5 JP2013503621 A5 JP 2013503621A5 JP 2012527383 A JP2012527383 A JP 2012527383A JP 2012527383 A JP2012527383 A JP 2012527383A JP 2013503621 A5 JP2013503621 A5 JP 2013503621A5
Authority
JP
Japan
Prior art keywords
lrg1
antagonist
seq
tumor
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012527383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503621A (ja
Filing date
Publication date
Priority claimed from GBGB0915515.1A external-priority patent/GB0915515D0/en
Application filed filed Critical
Publication of JP2013503621A publication Critical patent/JP2013503621A/ja
Publication of JP2013503621A5 publication Critical patent/JP2013503621A5/ja
Pending legal-status Critical Current

Links

JP2012527383A 2009-09-04 2010-09-06 血管増殖性疾患の治療 Pending JP2013503621A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0915515.1A GB0915515D0 (en) 2009-09-04 2009-09-04 Treatment of vasculoproliferative conditions
GB0915515.1 2009-09-04
PCT/GB2010/001681 WO2011027129A1 (en) 2009-09-04 2010-09-06 Treatment of vasculoproliferative conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015241950A Division JP6242847B2 (ja) 2009-09-04 2015-12-11 血管増殖性疾患の治療

Publications (2)

Publication Number Publication Date
JP2013503621A JP2013503621A (ja) 2013-02-04
JP2013503621A5 true JP2013503621A5 (cg-RX-API-DMAC7.html) 2013-10-24

Family

ID=41203240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012527383A Pending JP2013503621A (ja) 2009-09-04 2010-09-06 血管増殖性疾患の治療
JP2015241950A Active JP6242847B2 (ja) 2009-09-04 2015-12-11 血管増殖性疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015241950A Active JP6242847B2 (ja) 2009-09-04 2015-12-11 血管増殖性疾患の治療

Country Status (9)

Country Link
US (2) US8790647B2 (cg-RX-API-DMAC7.html)
EP (1) EP2473526B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013503621A (cg-RX-API-DMAC7.html)
CN (1) CN102596998B (cg-RX-API-DMAC7.html)
AU (1) AU2010290986B2 (cg-RX-API-DMAC7.html)
CA (1) CA2771965C (cg-RX-API-DMAC7.html)
ES (1) ES2647359T3 (cg-RX-API-DMAC7.html)
GB (1) GB0915515D0 (cg-RX-API-DMAC7.html)
WO (1) WO2011027129A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5717021B2 (ja) * 2009-12-03 2015-05-13 独立行政法人医薬基盤研究所 血管新生誘導分子
CA2866696A1 (en) * 2012-03-09 2013-09-12 Ucl Business Plc Treatment of cancer
TWI498425B (zh) * 2013-01-08 2015-09-01 Nat Univ Tsing Hua 層析濾紙型酵素連結免疫吸附分析法
JP6226315B2 (ja) * 2013-04-11 2017-11-08 国立大学法人高知大学 炎症性疾患の予防・治療剤、並びに炎症性疾患予防・治療薬のスクリーニング方法
WO2014197339A1 (en) 2013-06-08 2014-12-11 Apple Inc. Device, method, and graphical user interface for synchronizing two or more displays
CN103926413A (zh) * 2014-04-28 2014-07-16 刘红莉 一种用尿液进行癌症快速检测的试剂条的制备方法
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
CN106605266B (zh) * 2014-09-17 2019-10-18 东芝存储器株式会社 半导体装置
JP6675605B2 (ja) * 2014-10-10 2020-04-01 国立大学法人高知大学 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価
EP3243077B1 (en) 2015-01-05 2019-09-04 University Of Oslo Prostate cancer markers and uses thereof
GB201503438D0 (en) * 2015-02-27 2015-04-15 Ucl Business Plc Antibodies
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
KR102002866B1 (ko) * 2016-07-28 2019-07-23 인하대학교 산학협력단 Lrg1 당단백질을 포함하는 융합 단백질을 함유하는 발기부전, 허혈성 질환 또는 말초 신경질환의 예방 또는 치료용 조성물
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102661295B1 (ko) * 2021-01-22 2024-04-30 기초과학연구원 탈당화된 lrg1 당단백질 및 lrg1 당단백질 변이체, 및 이의 용도
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2025263529A1 (ja) * 2024-06-19 2025-12-26 国立大学法人東京科学大学 血管新生を処置する方法、および当該方法において用いるための免疫原性組成物
WO2026068571A1 (en) * 2024-09-25 2026-04-02 Singapore Health Services Pte. Ltd. Lrg1 antigen-binding molecules

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
ES2276405T3 (es) 1995-06-02 2007-06-16 Gilead Sciences, Inc. Ligandos de oligonucleotidos de alta afinidad a pdgf.
AU5087799A (en) * 1998-07-06 2000-01-24 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
US20050064516A1 (en) 2003-09-18 2005-03-24 Kantor Aaron B. Biological markers for diagnosing multiple sclerosis
SI2447283T1 (sl) * 2005-09-07 2015-12-31 Amgen Fremont Inc. Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1)
US7416850B2 (en) 2006-01-25 2008-08-26 Jemmerson Ronald R Cytochrome c and leucine-rich alpha-2-glycoprotein-1 assays, methods and antibodies
WO2008036741A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
AU2007301599B2 (en) * 2006-09-28 2013-01-10 Merck Serono S.A. Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
WO2008073919A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
WO2008092214A1 (en) 2007-02-02 2008-08-07 Minomic International Limited Biomarkers for diabetes
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
CA2699349C (en) * 2007-09-14 2016-04-19 Bayer Schering Pharma Aktiengesellschaft Substituted tricyclic heterocyclic compounds for use as egfr inhibitors
CL2008003302A1 (es) * 2007-11-09 2009-03-06 Genentech Inc Uso de una proteina de funsion kinasa 1 similar al receptor de activina (alk-1) y fc (alk1.fc) porque sirve para preparar un medicamento contra tumor,cancer o desordenes proliferativos.
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
WO2011015602A2 (en) 2009-08-04 2011-02-10 Biosystems International Sas Lung cancer biomarkers

Similar Documents

Publication Publication Date Title
JP6856694B2 (ja) Tim−3に対する抗体分子およびその使用
JP6676584B2 (ja) ポリペプチドワクチン
JP6423357B2 (ja) 二重特異性EGFR/c−Met抗体
CN102596998B (zh) 血管增殖病症的治疗
De Falco Antiangiogenesis therapy: an update after the first decade
Yarden et al. The ERBB network: at last, cancer therapy meets systems biology
ES2826774T3 (es) Anticuerpo que se une a ERBB-2 y ERBB-3
KR102659538B1 (ko) 자극성 및 비자극성 골수성 세포의 조절
AU2013347952B2 (en) EGFR and c-Met-fibronectin type III domain binding molecules
JP6470849B2 (ja) ニューロピリン1特異的結合ペプチド及びこのペプチドが融合された融合タンパク質及びその用途
ES2796090T3 (es) Uso de moduladores MCOLN-1 para regular la migración celular
JP2015516370A5 (cg-RX-API-DMAC7.html)
JP2015529641A5 (cg-RX-API-DMAC7.html)
WO2015109898A1 (zh) VEGF与PDGFRβ双特异性融合蛋白及其用途
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
JP2016536330A5 (cg-RX-API-DMAC7.html)
JP2015517300A5 (cg-RX-API-DMAC7.html)
CN105007939B (zh) 人抗vegfr-2/kdr抗体
RU2014118739A (ru) Способы ингибирования роста опухоли путем антагонизирования ил-6 рецептора
JP2014534237A5 (cg-RX-API-DMAC7.html)
CN109069602A (zh) 抑制scube2,一种新颖vegfr2辅助受体,抑制肿瘤血管发生
WO2019114793A1 (zh) 一种egfr抗体及其制备方法和应用
CN107531785B (zh) 人抗-vegfr-2/kdr抗体
Little Rational Design and Engineering of a Biparatopic Antibody Targeting CCR2 in Triple Negative Breast Cancer
WO2008131913A1 (en) Angiomotin-like protein 1-derived molecules for the modulation of angiogenesis and the treatment of tumours